FDA approves Guardant Health’s next-generation liquid biopsy panel
May 20, 2026
According to Guardant, Guardant360 Liquid assesses a ‘100x wider’ genomic footprint to guide cancer treatment decisioning than its predecessor.
According to Guardant, Guardant360 Liquid assesses a ‘100x wider’ genomic footprint to guide cancer treatment decisioning than its predecessor.
Sentante announced today that it received CE mark for its flagship endovascular surgical robot platform for treating stroke.
Researchers from Macao Polytechnic University, China, set out to look at how both exercise levels and cardiorespiratory fitness, as measured by VO2 max, affected the risk of cardiovascular disease.
Researchers from the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have reached a significant advance in the fight against type 1 diabetes.
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than current tests, according to a U.K.-wide study led by UCL researchers.
“These results provide encouraging evidence that targeting neuromuscular dysfunction can translate into meaningful clinical outcomes, aligning with our evolving understanding of the disease biology,” said first author Patrick John Strollo, MD, a sleep medicine physician at the University of Pittsburgh Medical Center.
SYDNEY, May 18, 2026 /PRNewswire/ — SeeTreat’s ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients’ changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.
Galvanize Therapeutics announced today that it received FDA clearance for its Aliya EX generator for the surgical ablation of soft tissue.
A team led by Cedars-Sinai Health Sciences University investigators has created a faster, cheaper way to determine the genes expressed in cancerous tumors. The AI-based tool, which they describe in the journal Cell, could make personalized cancer treatment available to more patients.
Researchers at Tampere University, Finland, have developed a groundbreaking 3D-printed ceramic implant material that closely mimics real human bone.